Patents by Inventor James E Polli

James E Polli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9597417
    Abstract: The present invention relates to the synthesis and use of a novel trifluorinated bile acid analog, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analog can be used as a 19F MRI tracer exhibiting an increased half-life due to its resistance to choloylglycine hydrolase.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 21, 2017
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMETN OF VETERANS AFFAIRS
    Inventors: James E. Polli, Jean-Pierre Raufman, Diana Vivian
  • Publication number: 20150132228
    Abstract: The present invention relates to the synthesis and use of a novel trifluorinated bile acid analogue, that being, CA-sar-TFMA which is useful as an imaging probe, diagnostic agent or contrast agent and is resistant to bacterial deconjugation, wherein the trifluorinated bile acid analogue can be used as a 19F MRI tracer exhibiting an increased half-life due to its resistance to choloylglycine hydrolase.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: JAMES E. POLLI, JEAN-PIERRE RAUFMAN, DIANA VIVIAN
  • Patent number: 8719043
    Abstract: A method is disclosed to verify and identify pharmaceutical products through their product signatures in order to combat counterfeiting and reduce dispensing errors, using methods such as near infrared spectroscopy. Furthermore, in order actively evade pharmaceutical product counterfeiting, a method is disclosed where an amount of one or more of the inactive ingredients is varied over time; the variation provides a different product signature, but falling within a level deemed permissible by a regulatory body.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: May 6, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: James E. Polli, Stephen W. Hoag
  • Publication number: 20030212051
    Abstract: Many compounds have poor bioavailability or variable bioavailability because of poor absorption of the compound in the small intestine. Conjugation of the compound with bile acid to form a prodrug will increase the bioavailibility of the compound and/or reduce the bioavailability variability of the compound because of the active transport of the prodrug by the intestinal bile acid transporter and because of increased lipophilic nature of the prodrug. A linker group can be used between the bile acid and the compound. One example of a bile acid containing prodrug is acyclovir valylchenodeoxycholate, where valine is the linker group. Another example of this prodrug is atenolol cholic acid amide.
    Type: Application
    Filed: March 21, 2003
    Publication date: November 13, 2003
    Inventors: James E Polli, Andrew Coop, Dean Y Maeda, Kimberly A Lentz